Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VALEANT PHARMACEUTICALS INTL INC T.VRX

"Valeant Pharmaceuticals is a global specialty pharmaceutical firm with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The firm also has a branded generics business that operates primarily in Latin America, Eastern Europe, and Asia."


TSX:VRX - Post by User

Comment by wallop13on Apr 22, 2016 12:08am
164 Views
Post# 24797469

RE:Valeant wants Perrigo's Papa as its new CEO: CNBC

RE:Valeant wants Perrigo's Papa as its new CEO: CNBCMr. Joseph C. Papa, also known as Joe, has been the Chief Executive Officer of Perrigo Company Public Limited Company since joining on October 9, 2006 and has been its Chairman since October 31, 2007. Mr. Papa serves as Chairman and Chief Executive Officer of Wrafton Laboratories Ltd. He serves as the President at Perrigo Company of Tennessee Inc. He serves as the Chairman and Chief Executive Officer of Perrigo Company Of South Carolina, Inc. He serves as the President of SPC Trademarks, LLC. He served as the President of Perrigo Company Public Limited Company from October 2006 to October 22, 2015. He served as the Chairman and Chief Executive Officer of Pharmaceutical Technologies & Services Business of Cardinal Health, Inc. from December 2004 to October 2006. He served as the President of Actavis, Inc. from October 2002 to November 19, 2004 and served as its Chief Operating Officer from November 2001 to November 19, 2004. Prior to joining Actavis, Inc., he served as the President and Chief Operating Officer of DuPont Pharmaceuticals from February 2001 to November 2001. From September 1997 to April 2000, Mr. Papa served as the President of US Operations of Searle Pharmaceuticals Company. In 1999, he led the team that launched the arthritis pain medication Celebrex in the US, widely regarded as the most successful new therapy launch at the time. He held management positions at G.D. Searle & Company, Novartis AG, Novartis Pharmaceuticals Corp., Ciba Geigy Pharmaceuticals and Geneva Pharmaceuticals. He began his career as a Pharmacist. He served as a Consulting Intern in the health care group of Ernst & Whinney. Mr. Papa has been a Director of Perrigo Company Public Limited Company since November 10, 2006. He has been an Independent Non-Executive Director of Smith & Nephew plc and Smith & Nephew, Inc. since August 1, 2008. Mr. Papa has a Bachelor of Science degree in Pharmacy from the University of Connecticut in 1978 and Master of Business Administration degree in Marketing and Finance from Northwestern University's Kellogg Graduate School of Management in 1983
<< Previous
Bullboard Posts
Next >>